Emergent BioSolutions Sees Unusually High Options Volume (NYSE:EBS)

Emergent BioSolutions Inc. (NYSE:EBSGet Free Report) was the target of some unusual options trading on Thursday. Stock traders acquired 5,129 put options on the company. This represents an increase of approximately 305% compared to the typical volume of 1,265 put options.

Insider Activity at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 10,000 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total value of $61,100.00. Following the completion of the sale, the director now owns 54,482 shares in the company, valued at $332,885.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 12,919 shares of company stock worth $75,831 in the last quarter. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Emergent BioSolutions

Large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 92.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 182,892 shares of the biopharmaceutical company’s stock worth $622,000 after buying an additional 87,654 shares in the last quarter. Quantbot Technologies LP lifted its stake in shares of Emergent BioSolutions by 218.7% during the third quarter. Quantbot Technologies LP now owns 8,700 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 5,970 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Emergent BioSolutions by 44.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,561,050 shares of the biopharmaceutical company’s stock valued at $5,308,000 after acquiring an additional 482,632 shares during the period. Shell Asset Management Co. boosted its holdings in Emergent BioSolutions by 757.6% in the third quarter. Shell Asset Management Co. now owns 46,970 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 41,493 shares during the last quarter. Finally, Hsbc Holdings PLC increased its position in Emergent BioSolutions by 295.4% in the third quarter. Hsbc Holdings PLC now owns 75,133 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 56,129 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Benchmark restated a “buy” rating and set a $5.00 target price on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

Read Our Latest Analysis on Emergent BioSolutions

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $6.26 on Friday. The stock has a market capitalization of $328.02 million, a price-to-earnings ratio of -0.57 and a beta of 1.64. The firm’s 50-day moving average price is $3.63 and its two-hundred day moving average price is $2.74. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $9.96.

Emergent BioSolutions (NYSE:EBSGet Free Report) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of ($3.65) by $4.24. The business had revenue of $300.40 million for the quarter. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. During the same period in the previous year, the firm earned ($3.17) earnings per share. On average, equities analysts predict that Emergent BioSolutions will post -1.98 earnings per share for the current fiscal year.

Emergent BioSolutions Company Profile

(Get Free Report)

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

Read More

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.